Drug Trial Radar · NCT06914128
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Mar 21, 2025
Primary completion
Jun 18, 2029
Study completion Jun 18, 2029
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Apr 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors. For this, the researchers will study and analyze: * the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity. * the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose. * the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses. * the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses. Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse. The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase. Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems. Participants will visit the study site: * at least twice before the treatment starts * multiple times when they start taking the treatment * once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason During the study, the doctors and their study team will: * check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram * check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan * take tumor samples The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.
Conditions
- MTAP-deleted Solid Tumors
Interventions
BAY 3713372Drug
Daily oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
- Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
- Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
- Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)Time frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
- Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTsTime frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
- Dose Escalation (Master and Intervention Cohort 1): Maximum concentration (Cmax) of the respective dosing interval of BAY 3713372Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days)
- Dose Escalation (Master and Intervention Cohort 1): Area under the curve (AUC) of the respective dosing interval of BAY 3713372Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days)
- Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)Time frame: Approximately 1.5 years
- Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTsTime frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
- Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
- Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
- Intervention Cohort 7: Number of participants with DLTsTime frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
- Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372Time frame: From first dose through day of surgery (approximately 7 ± 2 days)
- Intervention Cohort 7: Tumor tissue SDMA levelsTime frame: From first dose through day of surgery (approximately 7 ± 2 days)
Locations
62 sites in 13 countries. Site status is shown where the registry gives one.
UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
Birmingham, Alabama · Not yet recruiting
City of Hope - Duarte Cancer Center
Duarte, California · Not yet recruiting
UCLA Health Bowyer Oncology Center
Los Angeles, California · Not yet recruiting
UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
San Francisco, California · Recruiting
Stanford University Medical Center - Neurology
Stanford, California · Not yet recruiting
UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
Aurora, Colorado · Not yet recruiting
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
Denver, Colorado · Recruiting
Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
Orlando, Florida · Recruiting
Massachusetts General Hospital - Neurology
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute - Oncology Department
Boston, Massachusetts · Not yet recruiting
START | Midwest
Grand Rapids, Michigan · Recruiting
Icahn School of Medicine at Mount Sinai - Oncology
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, New York · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
NEXT Dallas - Oncology Department
Irving, Texas · Recruiting
START | San Antonio
San Antonio, Texas · Recruiting
Froedtert Hospital - Clinical Cancer Center
Milwaukee, Wisconsin · Not yet recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
Concord, New South Wales, Australia · Recruiting
Northern Hospital
Epping, New South Wales, Australia · Not yet recruiting
Calvary Mater Hospital Newcastle - Oncology
Waratah, New South Wales, Australia · Recruiting
Antwerp University Hospital | Oncology Department
Antwerp, Antwerp, Belgium · Recruiting
Ghent University Hospital | Drug Research Unit Department
Ghent, East Flanders, Belgium · Recruiting
UZ Leuven Gasthuisberg - Pneumology Department
Leuven, Flemish Brabant, Belgium · Recruiting
Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
Liège, Liège, Belgium · Recruiting
Beijing Cancer Hospital - Oncology Department
Beijing, Beijing Municipality, China · Recruiting
Beijing chest hospital, Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
Wuhan, Hubei, China · Recruiting
Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Not yet recruiting
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, Zhejiang, China · Not yet recruiting
Fakultní nemocnice Olomouc - Onkologická klinika
Olomouc, Olomouc Region, Czechia · Recruiting
Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)
Brno, South Moravian, Czechia · Recruiting
Rigshospitalet Copenhagen University Hospital | Oncology Department
Copenhagen, Capital Region / Region Hovedstaden, Denmark · Recruiting
Odense University Hospital | Svendborg Sygehus - Oncology Department
Odense, Region of Southern Denmark / Region Syddanmark, Denmark · Recruiting
Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
Aviano, Friuli Venezia Giulia, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
Rome, Lazio, Italy · Recruiting
I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
Rome, Lazio, Italy · Not yet recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
Milan, Lombardy, Italy · Recruiting
Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
Rozzano, Lombardy, Italy · Recruiting
Nagoya University Hospital
Nagoya, Aichi-ken, Japan · Not yet recruiting
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.